Which has grown faster, DXCM or MRNA?

Over the past five years, DXCM grew revenue faster — DXCM at a 18.91% CAGR versus MRNA at -2.60%.

Is DXCM or MRNA more profitable?

DXCM runs the higher net margin — DXCM at 19.31% versus MRNA at -143.55%.

Which has been the better investment, DXCM or MRNA?

Over the past 5-year, DXCM delivered the higher annualized total return — DXCM at 14.98% versus MRNA at -22.48%. Past performance doesn't predict future results.

DexCom, Inc. (DXCM) vs Moderna, Inc. (MRNA)

DXCM leads on 8 of 10 compared metrics.

A side-by-side comparison of DexCom, Inc. and Moderna, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 17, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).

Total return — DXCM vs MRNA

growth of $100 · last 8y

DXCM +126.0%MRNA +197.8%MRNA compounded faster

DXCM MRNA

DXCM vs MRNA: by the numbers

•DXCM is the larger company ($28.23B vs $21.98B market cap).
•DXCM is profitable (19.31% net margin) while MRNA runs a net loss (-143.55%).
•DXCM grew revenue faster over the past five years (18.91% vs -2.60% CAGR).

Which is better, DXCM or MRNA?

Metric tally: DXCM 8 · MRNA 2

It depends on what you're optimizing for:

GrowthDXCM(faster 5Y revenue CAGR)

QualityDXCM(higher ROIC)

Metrics side by side

Valuation

Metric	DXCM	MRNA
P/E ratio	31.26	—
Forward P/E	23.70	—
P/S ratio	5.98●	9.84
P/B ratio	9.74	2.95●
PEG ratio	0.66	—
EV / EBITDA	19.69	—
FCF yield	4.96%	—

Profitability

Metric	DXCM	MRNA
Gross margin	61.84%●	-13.89%
Operating margin	21.45%●	-153.35%
Net margin	19.31%●	-143.55%
ROE	31.47%●	-43.12%
ROIC	16.61%●	-29.70%

Growth (annualized)

Metric	DXCM	MRNA
Revenue CAGR (5Y)	18.91%●	-2.60%
EPS CAGR (5Y)	10.31%	—
FCF CAGR (5Y)	43.37%	126.92%●
Total return CAGR (5Y)	-6.24%●	-22.48%

Frequently asked

Which is better, DXCM or MRNA?: It depends on your goal. growth: DXCM (faster 5Y revenue CAGR); quality: DXCM (higher ROIC). Across all compared metrics, DXCM leads 8 to 2.
Which has grown faster, DXCM or MRNA?: Over the past five years, DXCM grew revenue faster — DXCM at a 18.91% CAGR versus MRNA at -2.60%.
Is DXCM or MRNA more profitable?: DXCM runs the higher net margin — DXCM at 19.31% versus MRNA at -143.55%.
Which has been the better investment, DXCM or MRNA?: Over the past 5-year, DXCM delivered the higher annualized total return — DXCM at 14.98% versus MRNA at -22.48%. Past performance doesn't predict future results.

Go deeper

Full DXCM analysis Full MRNA analysis Interactive comparison tool

Dig into the metrics

DexCom P/E ratio Moderna P/E ratio DexCom dividend yield Moderna dividend yield DexCom ROE Moderna ROE DexCom operating margin Moderna operating margin DexCom revenue growth Moderna revenue growth DexCom free cash flow Moderna free cash flow

DexCom & Moderna appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest FCF Yield Stocks Best 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 17, 2026.